Welcome to LookChem.com Sign In|Join Free
  • or
1(2H)-Quinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-nitro-, 1,1-dimethylethyl ester, commonly known as Telmisartan, is a pharmaceutical compound that belongs to the class of angiotensin II receptor antagonists. It is characterized by its ability to block the action of angiotensin, a substance that causes blood vessels to constrict, leading to increased blood pressure. Telmisartan functions by relaxing the blood vessels, allowing for smoother blood flow and consequently lowering blood pressure. It is typically administered orally in tablet form and is often prescribed alongside other medications to achieve optimal blood pressure control.

873056-11-2

Post Buying Request

873056-11-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

873056-11-2 Usage

Uses

Used in Pharmaceutical Industry:
Telmisartan is used as an antihypertensive agent for the treatment of high blood pressure. It helps in reducing the risk of stroke, heart attack, and kidney problems by effectively managing blood pressure levels. As an angiotensin II receptor antagonist, it plays a crucial role in the prevention and management of cardiovascular diseases.
Used in Combination Therapy:
Telmisartan is often used in combination with other medications to enhance its effectiveness in controlling blood pressure. This combination therapy allows for better management of hypertension and reduces the risk of associated complications, such as stroke, heart attack, and kidney problems.

Check Digit Verification of cas no

The CAS Registry Mumber 873056-11-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,3,0,5 and 6 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 873056-11:
(8*8)+(7*7)+(6*3)+(5*0)+(4*5)+(3*6)+(2*1)+(1*1)=172
172 % 10 = 2
So 873056-11-2 is a valid CAS Registry Number.

873056-11-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 4,4-dimethyl-7-nitro-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:873056-11-2 SDS

873056-11-2Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

-

, (2015/09/22)

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

-

, (2012/12/14)

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

-

, (2012/04/23)

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 873056-11-2